Related Experiment Video
Updated: Dec 20, 2025
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
21.6K
[Immunotherapy in bladder cancer-quo vadis? Update on current trials and developments]
1Studienpraxis Urologie, Nürtingen, Deutschland.
Der Urologe. Ausg. A
|May 30, 2020
Summary
Checkpoint inhibitors (CPIs) are now standard for advanced urothelial carcinoma. Further research is needed for biomarker selection and combination therapies in bladder cancer treatment.
Area of Science:
- Oncology
- Immunotherapy
- Urothelial Carcinoma Treatment
Background:
- Checkpoint inhibitors (CPIs) have advanced urothelial carcinoma treatment.
- CPIs are approved for metastatic or locally advanced inoperable urothelial carcinoma post-chemotherapy or for cisplatin-ineligible patients with high PD-L1 expression.
- CPIs are not yet approved for nonmuscle invasive bladder cancer (NMIBC) or muscle invasive bladder cancer (MIBC) curative therapy in Germany.
Purpose of the Study:
- To overview the current immunotherapy landscape for urothelial carcinoma.
- To identify challenges in the current therapeutic landscape.
Main Methods:
- Literature review of published data via PubMed search.
- Summary of the current therapeutic landscape and challenges.
Main Results:
- CPIs are the standard of care for metastatic or inoperable urothelial carcinoma.
- Potential expansion of CPI use to the perioperative setting (neoadjuvant/adjuvant) and BCG-unresponsive NMIBC is under discussion.
- Ongoing trials are evaluating these expanded indications.
Conclusions:
- Immunotherapy with CPIs is integral to managing advanced bladder cancer.
- Further investigation is urgently required for biomarker-based patient selection.
- Clinical trials are essential for developing combination therapies.
Related Concept Videos
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:30Cancer Vaccines
868
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
868
02:57Targeted Cancer Therapies
8.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.5K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K